<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02592018</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457AUS04T</org_study_id>
    <nct_id>NCT02592018</nct_id>
  </id_info>
  <brief_title>Immunologic Response to Secukinumab in Plaque Psoriasis</brief_title>
  <official_title>Characterization of the Response to Secukinumab in Plaque Psoriasis Using Novel Immunologic and Genetic Profiling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, open-label study, which will examine the effect of secukinumab on the&#xD;
      immunologic and genetic environment within psoriatic lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Quantitative analysis of the immunologic changes in immune cell populations will be performed&#xD;
      after secukinumab treatment in 15 patients at weeks 2, 4, and 12 compared to baseline week 0.&#xD;
      The immunologic profiles in psoriasis patients will also be compared to healthy control skin&#xD;
      surgical discard specimens (n=10). The number of differentially expressed genes in each cell&#xD;
      population will be quantified by RNA-seq at weeks 2, 4, 12 after secukinumab compared to&#xD;
      baseline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Percentage of CD4+ T Effector Cells Expressing IL17 Compared to Baseline</measure>
    <time_frame>Baseline to Week 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Percentage of CD4+ T Effector Cells Expressing IL17 Compared to Baseline</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Percentage of CD4+ T Effector Cells Expressing IL17 Compared to Baseline</measure>
    <time_frame>Baseline to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Differentially Expressed Genes in CD4+ Effectors Compared to Baseline Across All Participants</measure>
    <time_frame>Baseline to Week 2</time_frame>
    <description>by RNA-seq</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Differentially Expressed Genes in CD4+ Effectors Compared to Baseline</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>by RNA-seq</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Differentially Expressed Genes in CD4+ Effectors Compared to Baseline</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>by RNA-seq</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Differentially Expressed Genes in CD4+ T Regs Compared to Baseline</measure>
    <time_frame>Baseline to Week 2</time_frame>
    <description>by RNA-seq</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Differentially Expressed Genes in CD4+ T Regs Compared to Baseline</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>by RNA-seq</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Differentially Expressed Genes in CD4+ T Regs Compared to Baseline</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>by RNA-seq</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Differentially Expressed Genes in CD8+ T Effectors Compared to Baseline</measure>
    <time_frame>Baseline to Week 2</time_frame>
    <description>by RNA-seq</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Differentially Expressed Genes in CD8+ T Effectors Compared to Baseline</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>by RNA-seq</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Differentially Expressed Genes in CD8+ T Effectors Compared to Baseline</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>by RNA-seq</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Secukinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.</description>
    <arm_group_label>Secukinumab</arm_group_label>
    <other_name>Cosentyx</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to provide written informed consent and comply with the protocol.&#xD;
&#xD;
          2. At least 18 years of age.&#xD;
&#xD;
          3. Diagnosis of predominately plaque psoriasis for at least 6 months prior to enrollment.&#xD;
&#xD;
          4. Subject is considered a candidate for phototherapy or systemic therapy&#xD;
&#xD;
          5. PASI ≥ 12&#xD;
&#xD;
          6. PGA ≥ 3&#xD;
&#xD;
          7. Subject has a negative Quantiferon Gold, or if positive undergoes CXR. If CXR&#xD;
             negative, subject initiated prophylactic therapy with isoniazid for a course of 9&#xD;
             months with one month of therapy completed prior to first dose of secukinumab.&#xD;
&#xD;
          8. Subject is unlikely to conceive (male, post-menopausal, or using adequate oral&#xD;
             contraceptive therapy or IUD).&#xD;
&#xD;
          9. Physical exam within clinically acceptable limits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is unable to provide written informed consent or comply with the protocol.&#xD;
&#xD;
          2. Subject is younger than 18 years of age.&#xD;
&#xD;
          3. Subject has predominately non-plaque form of psoriasis.&#xD;
&#xD;
          4. Subject with mild psoriasis (PASI&lt;12 and PGA&lt;3) or is not a candidate for phototherapy&#xD;
             or systemic treatments.&#xD;
&#xD;
          5. Subject has drug-induced psoriasis.&#xD;
&#xD;
          6. Subject with current, or a history of, severe psoriatic arthritis well controlled on&#xD;
             current therapy.&#xD;
&#xD;
          7. Subjects with a serum creatinine level exceeding 176.8 μmol/L (2.0 mg/dl).&#xD;
&#xD;
          8. Screening total white blood cell (WBC count) &lt; 2,500/μl, platelets &lt; 100,000/μl,&#xD;
             neutrophils &lt; 1,500/μl, or hemoglobin &lt;8.5 g/dl.&#xD;
&#xD;
          9. Evidence of active tuberculosis infection as defined by a positive QuantiFERON TB-Gold&#xD;
             test (QFT) with a positive chest X-ray at screening, or untreated latent tuberculosis&#xD;
             defined by positive QFT with a negative chest X-ray without prophylactic therapy with&#xD;
             isoniazid for a course of 9 months with one month of therapy completed prior to first&#xD;
             dose of secukinumab.&#xD;
&#xD;
         10. History of an ongoing, chronic or recurrent infectious disease including past medical&#xD;
             history record of HIV, hepatitis B or hepatitis C.&#xD;
&#xD;
         11. Subjects possess other diagnoses that, in the investigator's opinion, preclude him/her&#xD;
             from safely participating in this study or interfere with the evaluation of the&#xD;
             subject's psoriasis.&#xD;
&#xD;
         12. History of known or suspected intolerance to any of the ingredients of the&#xD;
             investigational study product.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilson Liao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Psoriasis and Skin Treatment Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 16, 2015</study_first_submitted>
  <study_first_submitted_qc>October 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2015</study_first_posted>
  <results_first_submitted>June 23, 2020</results_first_submitted>
  <results_first_submitted_qc>August 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 27, 2020</results_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 14, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT02592018/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Secukinumab</title>
          <description>All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.&#xD;
Secukinumab: Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Secukinumab</title>
          <description>All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.&#xD;
Secukinumab: Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" lower_limit="29" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian/Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Family history of psoriasis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Percentage of CD4+ T Effector Cells Expressing IL17 Compared to Baseline</title>
        <time_frame>Baseline to Week 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.&#xD;
Secukinumab: Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage of CD4+ T Effector Cells Expressing IL17 Compared to Baseline</title>
          <units>percent change from week 0</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.42" spread="4.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Percentage of CD4+ T Effector Cells Expressing IL17 Compared to Baseline</title>
        <time_frame>Baseline to Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.&#xD;
Secukinumab: Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage of CD4+ T Effector Cells Expressing IL17 Compared to Baseline</title>
          <units>percent change from week 0</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="8.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Percentage of CD4+ T Effector Cells Expressing IL17 Compared to Baseline</title>
        <time_frame>Baseline to Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.&#xD;
Secukinumab: Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage of CD4+ T Effector Cells Expressing IL17 Compared to Baseline</title>
          <units>percent change from week 0</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="8.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Number of Differentially Expressed Genes in CD4+ Effectors Compared to Baseline Across All Participants</title>
        <description>by RNA-seq</description>
        <time_frame>Baseline to Week 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.&#xD;
Secukinumab: Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Differentially Expressed Genes in CD4+ Effectors Compared to Baseline Across All Participants</title>
          <description>by RNA-seq</description>
          <units>genes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Number of Differentially Expressed Genes in CD4+ Effectors Compared to Baseline</title>
        <description>by RNA-seq</description>
        <time_frame>Baseline to Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.&#xD;
Secukinumab: Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Differentially Expressed Genes in CD4+ Effectors Compared to Baseline</title>
          <description>by RNA-seq</description>
          <units>number of genes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Number of Differentially Expressed Genes in CD4+ Effectors Compared to Baseline</title>
        <description>by RNA-seq</description>
        <time_frame>Baseline to Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.&#xD;
Secukinumab: Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Differentially Expressed Genes in CD4+ Effectors Compared to Baseline</title>
          <description>by RNA-seq</description>
          <units>number of genes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Number of Differentially Expressed Genes in CD4+ T Regs Compared to Baseline</title>
        <description>by RNA-seq</description>
        <time_frame>Baseline to Week 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.&#xD;
Secukinumab: Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Differentially Expressed Genes in CD4+ T Regs Compared to Baseline</title>
          <description>by RNA-seq</description>
          <units>number of genes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Number of Differentially Expressed Genes in CD4+ T Regs Compared to Baseline</title>
        <description>by RNA-seq</description>
        <time_frame>Baseline to Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.&#xD;
Secukinumab: Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Differentially Expressed Genes in CD4+ T Regs Compared to Baseline</title>
          <description>by RNA-seq</description>
          <units>number of genes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Number of Differentially Expressed Genes in CD4+ T Regs Compared to Baseline</title>
        <description>by RNA-seq</description>
        <time_frame>Baseline to Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.&#xD;
Secukinumab: Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Differentially Expressed Genes in CD4+ T Regs Compared to Baseline</title>
          <description>by RNA-seq</description>
          <units>number of genes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Number of Differentially Expressed Genes in CD8+ T Effectors Compared to Baseline</title>
        <description>by RNA-seq</description>
        <time_frame>Baseline to Week 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.&#xD;
Secukinumab: Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Differentially Expressed Genes in CD8+ T Effectors Compared to Baseline</title>
          <description>by RNA-seq</description>
          <units>number of genes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Number of Differentially Expressed Genes in CD8+ T Effectors Compared to Baseline</title>
        <description>by RNA-seq</description>
        <time_frame>Baseline to Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.&#xD;
Secukinumab: Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Differentially Expressed Genes in CD8+ T Effectors Compared to Baseline</title>
          <description>by RNA-seq</description>
          <units>number of genes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Number of Differentially Expressed Genes in CD8+ T Effectors Compared to Baseline</title>
        <description>by RNA-seq</description>
        <time_frame>Baseline to Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab</title>
            <description>All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.&#xD;
Secukinumab: Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of Differentially Expressed Genes in CD8+ T Effectors Compared to Baseline</title>
          <description>by RNA-seq</description>
          <units>number of genes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Secukinumab</title>
          <description>All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.&#xD;
Secukinumab: Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Bell's palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Wilson Liao</name_or_title>
      <organization>UCSF Department of Dermatology</organization>
      <phone>415-476-4701</phone>
      <email>wilson.liao@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

